Navigation Links
Intercept Pharmaceuticals Raises $25 Million Series B Financing
Date:1/25/2010

NEW YORK, Jan. 25 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the completion of a $25 million Preferred Series B financing by its majority shareholder Genextra S.p.A.

Dr. Mark Pruzanski, founder, President and CEO commented, "This financing is recognition of the success we have had advancing our lead compounds INT-747 and INT-777. Genextra's strong backing will enable us to advance our clinical programs while continuing to build our pipeline of novel small molecules targeting FXR, TGR5 and other bile acid receptors."

In conjunction with the financing, Dr. Lorenzo Tallarigo, CEO of Genextra and Intercept director, is assuming the role of Chairman. Dr. Tallarigo stated, "This financing adds substantially to Genextra's investment in Intercept. With two positive Phase II studies last year, the company has made great progress in validating the therapeutic utility of INT-747 and the novel class of compounds it belongs to more broadly."

About Intercept Pharmaceuticals

Intercept is a clinical stage biopharmaceutical company focused on discovering and developing small molecule drugs for the treatment of chronic fibrotic and metabolic diseases. The company's most advanced programs are focused on the development of modified bile acids that are selective for FXR, a nuclear receptor, and TGR5, a G protein-coupled receptor. Bile acid signaling through these receptors regulates key aspects of lipid, glucose and overall energy metabolism, while also serving to maintain the functional integrity of the liver, intestine and kidney, organs that are exposed to bile acid flux.

About INT-747 (first-in-cla
'/>"/>

SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
2. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
3. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
4. Amylin Pharmaceuticals to Webcast Year-End Financial Results
5. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
6. Sagent Pharmaceuticals Launches Pamidronate Disodium Injection
7. Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification
8. Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms
9. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
10. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
11. Oramed Pharmaceuticals Announces Filing of Two Registration Statements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... the 3% of the population that suffer from hyperhidrosis, ... and disabling.  While more than half of these people ... is a serious medical condition.  Finally, there is a ... Dr. Bruce Katz , Director ... New York , is leading an approved ...
(Date:5/22/2013)... May 22, 2013  Healthcare providers are ... content management (ECM) solution, for a ... System .  These organizations identified enterprise content ... will use OnBase to optimize their Meditech ... (Logo:  http://photos.prnewswire.com/prnh/20090130/65710LOGO  ) ...
(Date:5/22/2013)... , May 22, 2013 Pomerantz ... investigating claims on behalf of investors of Intuitive Surgical, ... ISRG ) (CUSIP: 46120E602) who purchased Intuitive Surgical common ... (the "Class Period"). Such investors are advised to contact ... rswilloughby@pomlaw.com or 888-476-6529, ext. 237. The ...
Breaking Medicine Technology:Is There Finally A Way To Stop Severe Excessive Sweating? 2Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 2Three New Health Systems Integrate Hyland Software's OnBase with Meditech Hospital Information System 3SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intuitive Surgical, Inc. - ISRG 2
... Jan. 27 Genomic Health, Inc. (Nasdaq: GHDX ) today ... Wednesday, February 3 at 4:30 p.m. Eastern Time to discuss ... follow the release of the fourth quarter financial results after market close. ... call on February 3 at 4:30 p.m. Eastern Time ...
... , STAMFORD, Conn. , Jan. 27 ... Food and Drug Administration (FDA) 510(k) approval has been received for ... sale in the U.S.  A fully automated digital table and ... in comparison to other general radiographic systems*.  It also includes special ...
Cached Medicine Technology:Genomic Health to Announce Fourth Quarter and Year-End 2009 Financial Results and Host Conference Call on Wednesday, February 3 2Now Approved: Fujifilm's FDR AcSelerate Direct Digital DR System 2Now Approved: Fujifilm's FDR AcSelerate Direct Digital DR System 3Now Approved: Fujifilm's FDR AcSelerate Direct Digital DR System 4
(Date:5/23/2013)... 23, 2013 OnSomble, Inc. has partnered ... of the professional role and empower nurses to work ... president of patient care services and chief nursing officer ... excellent clinicians, and we want to help them take ... to lead they must follow, encourage them to take ...
(Date:5/23/2013)... May 23, 2013 Group Home Buy ... home buyers were taken on a tour of the latest ... people to purchase houses in groups, thus availing a concession ... charge a nominal fee from the home buyers for the ... the only source of revenue for Group Home Buy will ...
(Date:5/23/2013)... Long-Term Care Insurance shopping site LTC Tree ... applicants for Long Term Care Insurance are approved by insurance ... decision to buy a Long Term Care Insurance policy is ... to purchase protection are increasingly being turned away by insurance ... A variety of chronic conditions appear to be responsible for ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 911 Signal USA ... expo will begin on May 22 and run through May ... and information about the company's emergency vehicle lights ... new 2013 Dodge Charger at the expo. , The Charger ... on the market and can be seen by visiting 911 ...
(Date:5/22/2013)... The surging growth in specialty beds continues ... claims to compare mattresses often proves a bit challenging ... blog , offers shoppers faced with this dilemma an ... article. , Titled “ Mattress Comparison Overview – Top ... through the basics of innerspring beds as well as ...
Breaking Medicine News(10 mins):Health News:OnSomble, Inc. Partners with The Aroostook Medical Center to Enhance Nurse Understanding of the Professional Role 2Health News:Group Home Buy, a Unique Facility for Home Buyers, Launched in Style 2Health News:More Baby Boomers Rejected by Long Term Care Insurance Companies 2Health News:More Baby Boomers Rejected by Long Term Care Insurance Companies 3Health News:911 Signal USA Attends the 2013 Southwest Police Fleet Expo 2Health News:Mattress Comparison Overview Released by The Sleepy Shopper; Compares Top Types and Brands 2
... made up from olive oil, glycerine and egg ... cardiac bypass surgery.// ,The journal of Catheterization ... which was led by Michael Savage, M.D., director, ... Philadelphia. ,The mixture is not swallowed, Dr. ...
... stressed the need for inter-state cooperation to prevent ... should create a good system of intelligence-cum-legal wing, ... They should share the information with all the ... ,Inaugurating the 37th Drug Consultative Committee meeting ...
... Neurobiologists have discovered why the aging brain produces ... and memory center.// The scientists said the finding, ... long crucial "progenitor" stem cells persist in the ... the possibility of treating various neurodegenerative disorders, including ...
... together to educate Muslims on the necessity of vaccinating ... children belonging to the community. ,Lucknow's maulanas, or ... Rotary International that has been closely involved with the ... to join the vaccination teams, which face Muslim resistance ...
... adults developing symptoms of diabetes and heart disease, lifestyle ... cardiac problems. //A longitudinal study suggests that by reducing ... of life would reduce their risk of developing cardiac ... associated problems such as hypertension and type-2 diabetes has ...
... the results from a NIH funded clinical trials, the ... along with other botanical supplements failed to relieve hot ... the Herbal Alternatives (HALT) for Menopause Study. ... of Health (NIH), found that women using menopausal hormone ...
Cached Medicine News:Health News:Olive Oil Emulsions Prevent Cardiac Bypass Surgery 2Health News:Stem Cell Activity Deciphered in the Aging Brain 2Health News:Muslim Clerics to Join Hands to Eradicate Polio 2Health News:Cardiac Risk is Reduced by Cutting the Sugar in Your Drink 2Health News:Cardiac Risk is Reduced by Cutting the Sugar in Your Drink 3Health News:Herbal Supplements Fail to Relieve Hot Flushes 2Health News:Herbal Supplements Fail to Relieve Hot Flushes 3
Indications For Usage: ,Adult (recommended tidal volume >150ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to ...
Indications For Usage: ,Adult (recommended tidal volume >150ml), single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to...
... The Portex® Thermovent® T helps provide protection to ... is small and extremely lightweight making it ideal ... With a high rate of heat and moisture ... retention., ,All HMEs and filters have ISO ...
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
Medicine Products: